Previously, a PPAR-γ stimulating drug used in type 2 diabetes mellitus treatment (pioglitazone) was shown to inhibit ACKR3 expression in differentiated macrophages which resulted in suppressed chemotaxis [22]. Here, ACKR3 is linked to type 2 diabetes mellitus.